ANI publishes Phase 4 NEW DAY ILUVIEN DME trial results in Ophthalmology journal

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

ANIP

0.00
  • ANI Pharmaceuticals reported publication of Phase 4 NEW DAY trial results for ILUVIEN in diabetic macular edema in journal Ophthalmology; results were previously presented in July 2025.
  • Study supported use of ILUVIEN as baseline therapy in appropriate patients, reinforcing clinical evidence base for product in retina care.
  • Update shifts focus from conference disclosure to peer-reviewed validation, potentially strengthening payer and physician adoption narrative for ILUVIEN in DME.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.